Skip to main content
Figure 1 | Journal of Ovarian Research

Figure 1

From: Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB

Figure 1

Growth inhibition of human ovarian cancer cell lines A2780 (A) and C200 (B) treated with genistein (Gen), cisplatin (Cis), gemcitabine (Gem), taxotere (Tax) alone and the combination treatments were evaluated by the MTT assay. A2780 cells were treated with genistein (10 μM), cisplatin (250 nM), gemcitabine (2 nM) and taxotere (1 nM) and the combination treatment; and the C200 cells were treated with higher doses of genistein (25 μM), gemcitabine (50 nM) and doxetaxel (2 nM) as described under Materials and Methods. There was a significant reduction in the overall cell viability of A2780 and C200 cells treated with the drug combinations compared to cells treated with either drug alone. P values shown represent comparisons between each drug alone and the combination of both drugs using t-test.

Back to article page